BTIG Maintains Buy on AtriCure, Raises Price Target to $55

Benzinga Newsdesk www.benzinga.com Positive 81.8%

Neg 0% Neu 0% Pos 81.8%

BTIG analyst Marie Thibault maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $45 to $55.

Comments

No comments yet. Be the first!